Trial Profile

A Phase I/II Trial of INKmune (NK Cell Therapy) in Women with Relapsed Refractory Ovarian Cancer

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 11 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Inkmune (Primary)
Indications HER2 positive breast cancer; Ovarian cancer
Focus Adverse reactions; Therapeutic Use
Sponsors INmune Bio

Most Recent Events

03 Mar 2022 According to an INmune Bio media release, the company expects to initiate the phase I program in 2H 2022.
14 May 2020 According to an INmune Bio media release, due to COVID-19 pandemic the company now expects to enroll first patient in mid-2021.
11 Mar 2020 According to an INmune Bio media release, the company expects to enroll first patient in this study in 2H 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com